Novo Nordisk CEO: People have been waiting for a GLP-1 pill

Summary

Mike Doustdar, Novo Nordisk president and CEO, discusses the GLP-1 market and the opportunity for an oral GLP-1 pill with Jim Cramer. He says 10-15 million people are currently on GLP-1 therapy with Novo and its competitor, and that an oral pill could expand the market by addressing needle phobia, societal taboo, and refrigeration/cold-chain barriers. He also notes that obesity is a heterogeneous set of diseases with different patient needs, supporting multiple treatment modalities, though some patients still prefer weekly injections.

• Novo Nordisk CEO Mike Doustdar speaks with Jim Cramer about GLP-1 treatments.
• He estimates 10-15 million people currently use GLP-1 drugs across Novo and its competitor.
• An oral GLP-1 pill could expand the market by avoiding injections and refrigeration.
• Needle phobia, societal taboo, and cold-chain limits are key barriers to injectable GLP-1.
• Some patients prefer weekly injections, while others prefer a daily pill.
• Doustdar says obesity is not one condition but multiple diseases with different needs.
• He cites roughly 2 billion people with obesity as a large addressable market.
• The discussion implies multiple GLP-1 modalities can coexist and the market may broaden.